Cordlife GroupCLIFF 33 Altman Z-Score is 0.79 as of Jun. 26, 2026, which is 56% below its 10-year median of 1.78. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 67.65% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 0.79 is in distress zone. This implies bankruptcy possibility in the next two years.
Cordlife Group has a Altman Z-Score of 0.79, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Cordlife Group's Altman Z-Score or its related term are showing as below:
CLIFF'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.79 Med: 1.78 Max: 3.33
Current: 0.79
During the past 13 years, Cordlife Group's highest Altman Z-Score was 3.33. The lowest was 0.79. And the median was 1.78.
Cordlife Group (OTCPK:CLIFF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Cordlife Group Altman Z-Score Related Terms
Cordlife Group Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, IDXX: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Cordlife Group's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Cordlife Group's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.2381
+
1.4
*
0.2108
+
3.3
*
-0.0542
+
0.6
*
0.3273
+
1.0
*
0.1901
=
0.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Cordlife Group (CLIFF) has a Altman Z-Score of 0.79 as of Jun. 26, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Cordlife Group and its competitors. This is 56% below median its historical median of 1.78. Over the past decade, Cordlife Group's Altman Z-Score has ranged from 0.79 to 3.33. According to the industry distribution chart, Cordlife Group ranks #138 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 67.6%.
Is Cordlife Group's Altman Z-Score too high?
Cordlife Group's current Altman Z-Score of 0.79 is 56% below median its 10-year median of 1.78. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 3.33. The Medical Diagnostics & Research industry median Altman Z-Score is 2.40. Cordlife Group's value of 0.79 is 67% below this industry median. Based on the distribution chart, Cordlife Group ranks #138 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Altman Z-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #138 out of 204 companies for Altman Z-Score. This places Cordlife Group in the lower half of its industry. The industry median Altman Z-Score is 2.40. Cordlife Group's value of 0.79 is 67% below this benchmark. Historically, Cordlife Group's own Altman Z-Score has ranged from 0.79 to 3.33 over the past decade. While the company's 10-year median is 1.78 vs. the industry median of 2.40, Cordlife Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.40, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current Altman Z-Score of 0.79 is 67% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current Altman Z-Score is 0.79, which is 56% below median its own 10-year median of 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current Altman Z-Score is 0.79, which is 56% below median its 10-year median of 1.78 and 67% below the Medical Diagnostics & Research industry median of 2.40. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Altman Z-Score is 0.79 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
Altman Z-Score: 0.79 (56% below median its 10-year median of 1.78)
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
Industry Position: 67% below the Medical Diagnostics & Research median (#138 of 204)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
